Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bill.com Holdings Inc (BILL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Bill.com Holdings IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Bill.com Holdings Inc vs IDEXX Laboratories, Inc. — how do they compare? Bill.com Holdings Inc trades at $49.45 (market cap $4.93B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.4× Bill.com Holdings Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.

BILLIDXX
Market Cap
$4.93B$46.22B
Sector
TechnologyHealth
52-Week High
$56.32$766.68
52-Week Low
$31.96$526.44
Enterprise Value
$4.64B$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bill.com Holdings Inc

BILL Holdings trades at $48.63, down 1.28% on the day, with a bullish technical signal from moving averages and positive earnings beats in recent quarters. Revenue growth is strong, reaching $1.46B in 2025, but profitability remains thin with a net income margin of just 0.01%. The company is focusing on AI-driven automation and operational efficiency, including a recent 30% workforce reduction and new executive appointments to spur growth.

Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56%) and a price target implying modest upside. Key risks include intense fintech competition and the challenge of translating high revenue into sustained profitability. Cash flow trends show improvement, but investors should monitor execution on margin expansion and competitive positioning.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bill.com Holdings Inc

Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.

Read more on BILL

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX